SynthesisMedicine2018
The long-term efficacy of STN vs GPi deep brain stimulation for Parkinson disease: A meta-analysis.
Synthesis in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cost Effectiveness of Deep Brain Stimulation for Parkinson's Disease: A Systematic Review.Applied health economics and health policy · 2024Pooled it
- Gait and balance deterioration following deep brain stimulation in Parkinson's disease: a counterfactual review.Clinical parkinsonism & related disorders · 2026Review
- Will adaptive deep brain stimulation for Parkinson's disease become a real option soon? A Delphi consensus study.NPJ Parkinson's disease · 2025Article
- Comparison of different surgical strategies for cervical dystonia: Evidence from Bayesian network analysis.European journal of neurology · 2025Article
- Probabilistic mapping of the antiparkinsonian effects of pallidal deep brain stimulation.Brain communications · 2025Article
- Comparison of the Long-Term Efficacy of Targeting the Subthalamic Nucleus Versus the Globus Pallidus Interna for Deep Brain Stimulation Treatment of Motor Dysfunction in Patients With Parkinson's Disease: A Meta-Analysis Study.Parkinson's disease · 2024Review
- Deep Brain Stimulation for the Management of Refractory Neurological Disorders: A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2023Review
- Review
- Deep brain stimulation (DBS) as a therapeutic approach in gait disorders: What does it bring to the table?IBRO neuroscience reports · 2023Review
- Stereotactic Staged Asymmetric Bilateral Radiofrequency Lesioning for Parkinson's Disease.Stereotactic and functional neurosurgery · 2023Article
- Effects of deep brain stimulation target on the activation and suppression of action impulses.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2022Article
- Deep brain stimulation for parkinson's disease induces spontaneous cortical hypersynchrony in extended motor and cognitive networks.Cerebral cortex (New York, N.Y. : 1991) · 2022Article
- Review
- Quality of life of patients with Parkinson's disease: a comparison between preoperative and postoperative states among those who were treated with deep brain stimulation.Arquivos de neuro-psiquiatria · 2022Article
- Brain stimulation: a therapeutic approach for the treatment of neurological disorders.CNS neuroscience & therapeutics · 2022Review
- Effects of bilateral subthalamic nucleus deep brain stimulation on motor symptoms in Parkinson's disease: a retrospective cohort study.Neural regeneration research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis meta-analysis assessed the long-term efficacy of deep brain stimulation (DBS) of the subthalamic nucleus (STN) and globus pallidus interna (GPi) for Parkinson disease (PD).
methodsPubMed, Cochrane Library, and Clinical Trials databases were searched. Outcomes were unified Parkinson disease rating scale section (UPDRS) III off-medication score, Parkinson's disease questionnaire: 39 activities of daily living (PDQ-39 ADL) score, and levodopa-equivalent dosage after DBS.
resultsDuring the off-medication state, pooled weighted mean difference (WMD) of UPDRS III score was .69 (95% confidence interval [CI] = -1.77 to 3.16, P = .58). In subgroup analysis, WMD of UPDRS III off-medication scores from baseline to 2 years and 3 years post-DBS were -.61 (95% CI = -2.97 to 1.75, P = .61) and 2.59 (95% CI = -2.30 to 7.47, P = .30). Pooled WMD of changes in tremor, rigidity, and gait scores were 1.12 (95% CI = -0.05 to 2.28, P = .06), 1.22 (95% CI = -0.51 to 2.94, P = .17) and .37 (95% CI = -0.13 to 0.87, P = .15), respectively. After DBS, pooled WMD of PDQ-39 ADL and LED were -3.36 (95% CI = -6.36 to -0.36, P = .03) and 194.89 (95% CI = 113.16 to 276.63, P < .001).
conclusionsSTN-DBS and GPi-DBS improve motor function and activities of daily living for PD. Differences in the long-term efficacy for PD on motor symptoms were not observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.